Supha Pharmachem Enters Insolvency Over ₹7.47 Crore Default

Introduction

Supha Pharmachem Limited, previously known as Remedium Lifecare, has been admitted into the Corporate Insolvency Resolution Process (CIRP) by the National Company Law Tribunal (NCLT), Mumbai Bench. The order, dated March 17, 2026, was issued after the company defaulted on a payment of ₹7.47 crore. As a result of the NCLT's decision, the company's Board of Directors has been suspended, and a moratorium has been imposed on all legal and financial proceedings against it.

NCLT Initiates Insolvency Proceedings

The action was triggered by a petition filed by an operational creditor, Boston Ivy Healthcare Solution Private Limited, under Section 9 of the Insolvency and Bankruptcy Code (IBC), 2016. The NCLT found merit in the creditor's application, confirming that a default had occurred on November 7, 2023. With the admission into CIRP, a time-bound process to resolve the company's financial distress has officially begun. The tribunal has appointed Mr. Rajesh Jhunjhunwala as the Interim Resolution Professional (IRP) to oversee the process.

Board Suspended and IRP Takes Control

A significant consequence of the CIRP admission is the immediate suspension of the powers of Supha Pharmachem's Board of Directors. The management of the company's affairs now rests with the IRP, Mr. Rajesh Jhunjhunwala. His primary responsibilities include taking control of the company's assets, managing its operations, collecting all financial information, and collating claims submitted by creditors. The IRP will function as the manager of the corporate debtor during this period, ensuring the company continues as a going concern while a resolution is sought.

The Moratorium and Its Implications

Under Section 14 of the IBC, the NCLT has declared a moratorium, which prohibits the institution of new lawsuits or the continuation of existing suits against Supha Pharmachem. It also prevents any action to foreclose, recover, or enforce any security interest created by the company. This legal shield is designed to protect the company's assets from being dissipated during the resolution process, providing a stable environment for the IRP and creditors to work on a revival plan.

Understanding the Corporate Insolvency Resolution Process (CIRP)

The CIRP is a structured recovery mechanism for creditors under the IBC. The primary objective is not to liquidate the company but to find a resolution plan that can revive it. The process typically must be completed within 180 days, with a possible one-time extension of 90 days. During this period, the IRP will form a Committee of Creditors (CoC), comprising all financial creditors, which will then vote on potential resolution plans submitted by interested applicants.

Summary of Key Insolvency Details

Financial Health vs. Default

Interestingly, the insolvency proceedings come at a time when the company's last reported financials for the year ending March 31, 2024, showed significant growth. The company reported a total income of ₹40,627.88 crore, a substantial increase from ₹5,098.37 crore in the previous year. Profit for the same period stood at ₹32.73 crore, up from ₹5.43 crore. This stark contrast between robust reported financials and a default on a relatively small amount of ₹7.47 crore raises questions about the company's liquidity management and operational financial health.

Path Forward for Supha Pharmachem

The immediate next step is for all creditors-financial and operational-to submit their claims to the IRP by the deadline of March 31, 2026. Following this, the IRP will constitute the CoC, which will be the primary decision-making body. The CoC will either confirm Mr. Jhunjhunwala as the Resolution Professional (RP) or appoint a new one. The RP will then invite resolution plans from potential bidders. If the CoC approves a plan with a 66% majority vote, it will be submitted to the NCLT for final approval. If no viable plan is approved within the statutory timeline, the company may be pushed into liquidation.

Conclusion

Supha Pharmachem's entry into the CIRP marks a critical juncture for the company. The process under the IBC provides a structured framework for resolving its debt and potentially reviving its operations. The focus now shifts to the IRP's management and the CoC's ability to find and approve a sustainable resolution plan. Stakeholders, including employees, shareholders, and creditors, will be closely watching the developments over the coming months to determine the company's future.